TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 37.84% since Feb 24.
None of the estimates for this med-biomed/gene stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
TrovaGene has a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
A better-ranked stock in the same space is Acorda Therapeutics, Inc. (ACOR), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TROVAGENE INC (TROV): Get Free Report
ACORDA THERAPT (ACOR): Free Stock Analysis Report
To read this article on Zacks.com click here.
TrovaGene (TROV) in Focus: Stock Adds 6.1% in Session - Tale of the Tape
Terms and Privacy Policy